A staging system based on genetic markers could facilitate the stratification and prognostication of intracranial ependymomas, according to research published in the Journal of Clinical Oncology.

[4] The present study has attempted to evaluate CD99 as a possible specific marker that could selectively differentiate ependymomas from other CNS tumors. Both CD99 and EMA were also evaluated ...

Of the 29 classic ependymomas studied, 24 (82.76%) cases were intracranially located, whereas 14 of them (58.3%) were in the posterior fossa and 5 (17.24%) were located within the spinal region.